Trials / Not Yet Recruiting
Not Yet RecruitingNCT06634173
The Diagnostic Value of FAPI PET/CT in Staging of Newly Diagnosed Prostate Cancer
- Status
- Not Yet Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- The Netherlands Cancer Institute · Academic / Other
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to investigate the diagnostic value of FAPI PET/CT, relative to standard-of-care imaging using PSMA PET/CT, in staging of newly diagnosed PCa. FAPI PET/CT will be visually and quantitatively correlated to PSMA PET/CT resulting in detection rates and target-to-background ratios. If available, histopathology of resected specimens will serve as reference test for operated patients in order to determine diagnostic accuracy. All outcomes are descriptive and serve as pilot for a potential subsequent larger prospective diagnostic study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | FAPI PET/CT | This study applies the radiopharmaceutical 18Fluor-FAPI-74 (FAPI) for molecular imaging of FAP expression in vivo with FAPI PET/CT, to assess the presence and distribution of activated Cancer associated fibroblasts as a marker of Tumor Micro-Environment and indirectly as a marker for malignancies. |
Timeline
- Start date
- 2024-12-01
- Primary completion
- 2025-12-01
- Completion
- 2025-12-01
- First posted
- 2024-10-09
- Last updated
- 2024-10-09
Source: ClinicalTrials.gov record NCT06634173. Inclusion in this directory is not an endorsement.